Keywords: Watson, Natco, Celgene, Revlimid, Multiple myeloma, Generic version

Watson confirms deal with Natco for generic version of Celgene’s cancer drug Revlimid

Article | 08 December 2010

Print This

US generic drugs maker Watson Pharmaceuticals (NYSE: WPI) and India’s Natco Pharma (BSE: 524816) have confirmed an exclusive, US ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in